🎉 Congratulations! If you've got this POAP, you’re officially in the exclusive club of folks who are ready to break free from the Bayer CloudTech UserGroup email chain! 🥳 Time to wave goodbye to those inbox notifications! ✌️💌

Thanks for for taking the time to complete this survey, It was a pleasure seeing you in Madrid!

I collaborate with different functions to acquire, process and transform data using technologies for better insights and decision-making for Pharma R&D.​

I've met Miriam during a DS&AI meeting in May 2023 in Madrid. She works as a Data Steward within Data Strategy and Governance in the group Proprietary Information Management. She is a (computational) chemist by training and has particular experience with our chemical labjournal data.

Our vision at Data Science Services & Solutions, DS3, is to Enable, Scale, and Operationalize R&D Data Science & AI capabilities to achieve Clinical Research and Development Speed, Efficiency, and Optimization. Learn more about our areas of responsibility, capabilities, strategic priorities, and collaborations. For more information, contact DS3 Head: Abi Velurethu. Artwork created using Stable Diffusion.

Given the considerable amount of data that is collected throughout clinical trials, it can be asked if this data can be used to improve our understanding of the trial, regardless of outcome. The radiomics pilot seeks to provide a toolkit that is capable of analyzing the different modalities of information found in clinical trials (genome, gene expression, biomarker, clinical information, and imaging information) to derive insights into why a patient may be responding, or why a clinical trial was unsuccessful. The current efforts have focused on clinical trials in oncology, while collaborating with the RED-ONC function. Overall, the project is in its pilot state, and demonstrating a proof of concept, while documenting many challenges and learnings with the development of such a toolkit. Potential directions that could expand this toolbox include deriving the factors that best predict why a patient would stay in a clinical trial, and providing assistance with patient selection of clinical trials. Other potential directions involve suggesting why a particular trial may have been unsuccessful and providing that information back to the drug development team.

With the new head of R&D Community Engagement, RDCE, a new set-up has also been introduced, which newly regulates the tasks and responsibilities of the business partners assigned to the functions, SPOCs, which stands for Single Point of Contact. What is now in scope and what is not? The poster provides information on this.